Johnson & Johnson’s third quarter 2026 sales matched estimates at $25.4B while Innovative Medicine outperformed

Johnson & Johnson reported third quarter 2026 results featuring solid operational sales growth of 6.0%, driven by outperformance in its Innovative Medicine segment. While revenue of $25.4 billion met consensus, adjusted EPS of $2.59 fell short of the $2.66 estimate, impacted by acquisition costs for Firefly Bio and strategic collaborations. The company raised its full-year 2026 guidance, now expecting reported sales at a midpoint of $101.2 billion and adjusted EPS at $11.10.

Key Highlights

• Innovative Medicine sales grew 7.7% to $16.8 billion, led by Darzalex (+15.4%) and Carvykti (+35.5%), partially offsetting significant Stelara erosion.
• Stelara sales faced a 690 basis point headwind due to biosimilar competition, resulting in a worldwide sales decline of 17.3% to $2.02 billion.
• MedTech sales rose 2.5% to $8.6 billion, supported by the integration of Shockwave and growth in the Cardiovascular and Vision franchises.
• Significant pipeline progress was noted with the FDA market authorization of the OTTAVA robotic surgical system and the approval of IMAAVY for warm autoimmune hemolytic anemia.